A randomized, Double-blind, Placebo-controlled, multicentre proof-of-concept study to access safety, tolerability, phamacokinetics and efficacy of Radotinib in Parkinson's disease
Topic / Pathology
- Parkinson's Disease
Objectives
To have more informations, click on the link below:
https://clinicaltrials.gov/ct2/show/NCT04691661?term=il+yang&cond=Parki…
Sponsor
Il Yang Pharma
Status
Recruiting
